Dose-escalation, Repeated and Single Oral Dosing Study
Acute Coronary Syndrome

About this trial
This is an interventional screening trial for Acute Coronary Syndrome
Eligibility Criteria
Inclusion Criteria:
- a healthy adult between 20 and 45 years old at the time of visit for screening
- a person who is able to give written consent
- a person between 50 and 85 kg at the time of visit for screening
- a woman who is negative on a serum hCG test at the time of visit and the day before a trial, and who is not nursing, a woman who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, or who had a contraceptive operation no later than 120 days before visit for screening, or who is menopausal, a man who had a contraceptive operation no later than 120 days before visit for screening, or who agrees on double contraception, medically approved, from the time of visit for screening to 90 days after the last administration of a clinical trial drug, and also agree not to donate sperm
- a person more than hemoglobin 12 g/dL at the time of screening (a woman more than hemoglobin 11 g/dL)
- a person whose vital signs were in the normal range at the time of visit for screening, or who is medically determined not to be clinically significant by an investigator
Exclusion Criteria:
- a person with the medical history of gastric ulcer, duodenal ulcer or esophageal ulcer within 90 days from the time of visit for screening
- a person with the medical history of gastrointestinal diseases(e.g. Crohn's disease, ulcerative colitis, etc.) or surgery(excluding uncomplicated appendectomy or herniotomy) affecting the absorption of a clinical trial drug
- a person with the medical history of blood coagulation disorder or hemorrhagic diseases, or with clinically significant abnormal findings decided by a investigator on blood coagulation test at the time of screening
- a woman with the medical history of dysfunctional uterine bleeding within a year from the time of visit for screening
- a person with the medical history of epilepsy or convulsion
- a person with the medical history of internal organ transplant
- a person expected to be hard to complete a clinical trial because of surgery or medical procedures planned within a clinical trial period
- a person with the medical history of clinically significant new diseases within 30 days from the time of visit for screening according to investigator's decision
- a person with hypersensitivity reaction to a drug or gelatin, or the medical history of clinically significant hypersensitivity reaction
- a person with the history of drug abuse, or with a positive reaction to a drug possible to be abused on urine drug screening
- a person with the medical history of alcohol abuse within two years from the time of visit for screening
- a person who is a smoker, or with a positive reaction on a urine nicotine test conducted at the time of visit for screening
- a person who donated whole blood within 60 days or constituents of blood within 30 days, or received a blood transfusion within 30 days from the time of visit for screening
- a person taking other clinical trial drugs within 90 days from the time of visit for screening
- a person taking a prescription drug within 30 days, or a contraindicated drug or oriental medicine within 14 days from the time of visit for screening
- a person with a positive reaction to a serum test(hepatitis B test, hepatitis C test, HIV test, syphilis test)
- a person with hepatic enzymes(AST, ALT) more than 2.5 times of the reference upper limit(UNL) or total bilirubin more than 1.5 times of the reference upper limit(UNL) or creatinine more than 1.25 times of the reference upper limit(UNL)
- a person expected to be hard to complete a clinical trial due to physical or mental status according to investigator's medical decision at the time of visit for screening
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Arm 11
Arm 12
Arm 13
Arm 14
Arm 15
Arm 16
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Placebo Comparator
APD791 10mg single dose
APD791 20mg single dose
APD791 40mg single dose
APD791 10mg
APD791 20mg
APD791 40mg
APD791 80mg
APD791 160mg
APD791 240mg
APD791 320mg
APD791 Placebo
APD791 2mg MD
APD791 5mg MD
APD791 10mg MD
APD791 20mg MD
APD791 placebo MD
APD791 10mg single dose
APD791 20mg single dose
APD791 40mg single dose
APD791 10mg single dose + Aspirin + Clopidogrel
APD791 20mg single dose + Aspirin + Clopidogrel
APD791 40mg single dose + Aspirin + Clopidogrel
APD791 80mg single dose + Aspirin + Clopidogrel
APD791 160mg single dose + Aspirin + Clopidogrel
APD791 240mg single dose + Aspirin + Clopidogrel
APD791 320mg single dose + Aspirin + Clopidogrel
APD791 placebo for single dose + Aspirin + Clopidogrel
APD791 2mg multiple dose + Aspirin + Clopidogrel
APD791 5mg multiple dose + Aspirin + Clopidogrel
APD791 10mg multiple dose + Aspirin + Clopidogrel
APD791 placebo for multiple dose + Aspirin + Clopidogrel
APD791 placebo for multiple dose + Aspirin + Clopidogrel